Initiated the Phase 3 VELA program of the Nanobody ® sonelokimab in patients with moderate-to-severe hidradenitis suppurativa ...

At December 31, 2024, the Company's cash and cash equivalents grew to $912.8 million, compared to $713.7 million at December 31, 2023, which accounts for approximately $100.0 million of repurchased ...

United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced its financial results for the quarter and year ended December 31, 2024. Full year 2024 revenues rose to a ...